Literature DB >> 1152355

Diphenylhydantoin: correlation between protein binding and albumin concentration.

R Gugler, D L Azarnoff, D W Shoeman.   

Abstract

The unbound fraction of diphenylhydantoin is inversely correlated with the patient's serum albumin concentration and can be accurately estimated graphically without binding analyses. The data for this relationship was obtained from a study in which we observed that the unbound fraction of diphenylhydantoin was two times higher in patients with the nephrotic syndrome. However, in these patients it was not necessary to diminish the dosage since the absolute concentration of unbond drug was unchanged due to a compensatory increase in the apparent volume of distribution and plasma clearance.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1152355     DOI: 10.1007/bf01493371

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN: 0023-2173


  10 in total

1.  INSUFFICIENT PARAPHYDROXYLATION AS A CAUSE OF DIPHENYLHYDANTOIN TOXICITY.

Authors:  H KUTT; M WOLK; R SCHERMAN; F MCDOWELL
Journal:  Neurology       Date:  1964-06       Impact factor: 9.910

2.  Plasma protein binding of diphenylhydantoin in man. Interaction with other drugs and the effect of temperature and plasma dilution.

Authors:  P K Lunde; A Rane; S J Yaffe; L Lund; F Sjöqvist
Journal:  Clin Pharmacol Ther       Date:  1970 Nov-Dec       Impact factor: 6.875

Review 3.  Biochemical and genetic factors regulating dilantin metabolism in man.

Authors:  H Kutt
Journal:  Ann N Y Acad Sci       Date:  1971-07-06       Impact factor: 5.691

4.  Erythrocyte uptake and plasma binding of diphenylhydantoin.

Authors:  D Kurata; G R Wilkinson
Journal:  Clin Pharmacol Ther       Date:  1974-08       Impact factor: 6.875

5.  Antiserum to diphenylhydantoin: preparation and characterization.

Authors:  C E Cook; J A Kepler; H D Christensen
Journal:  Res Commun Chem Pathol Pharmacol       Date:  1973-05

6.  The alteration of plasma proteins in uremia as reflected in their ability to bind digitoxin and diphenylhydantoin.

Authors:  D W Shoeman; D L Azarnoff
Journal:  Pharmacology       Date:  1972       Impact factor: 2.547

7.  Plasma protein binding of diphenylhydantoin in patients with epilepsy. Agreement between the unbound fraction in plasma and the concentration in the cerebrospinal fluid.

Authors:  L Lund; A Berlin; K M Lunde
Journal:  Clin Pharmacol Ther       Date:  1972 Mar-Apr       Impact factor: 6.875

8.  SERUM DIPHENYLHYDANTOIN (PHENYTOIN) IN AMBULANT PATIENTS WITH EPILEPSY.

Authors:  M LUND; R S JORGENSEN; V KUEHL
Journal:  Epilepsia       Date:  1964-03       Impact factor: 5.864

9.  [The significance of cumulation and elimination for the determination of Phenytoin (diphenylhydantoin)].

Authors:  H Remmer; J Hirschmann; I Greiner
Journal:  Dtsch Med Wochenschr       Date:  1969-06-13       Impact factor: 0.628

10.  The rate of decline of diphenylhydantoin in human plasma.

Authors:  K Arnold; N Gerber
Journal:  Clin Pharmacol Ther       Date:  1970 Jan-Feb       Impact factor: 6.903

  10 in total
  7 in total

Review 1.  Disease-induced variations in plasma protein levels. Implications for drug dosage regimens (Part II).

Authors:  R Zini; P Riant; J Barré; J P Tillement
Journal:  Clin Pharmacokinet       Date:  1990-09       Impact factor: 6.447

2.  Effect of albumin distribution. A simulation analysis of the effect of altered albumin distribution on the apparent volume of distribution and apparent elimination rate constant of drugs.

Authors:  M Shimoda; E Kokue; T Hayama; T B Vree
Journal:  Pharm Weekbl Sci       Date:  1989-06-23

Review 3.  Drug protein binding and the nephrotic syndrome.

Authors:  R Gugler; D L Azarnoff
Journal:  Clin Pharmacokinet       Date:  1976       Impact factor: 6.447

4.  Mycophenolic acid pharmacokinetics and related outcomes early after renal transplant.

Authors:  Bronwyn A Atcheson; Paul J Taylor; David W Mudge; David W Johnson; Carmel M Hawley; Scott B Campbell; Nicole M Isbel; Peter I Pillans; Susan E Tett
Journal:  Br J Clin Pharmacol       Date:  2005-03       Impact factor: 4.335

5.  The EMIT FreeLevel ultrafiltration technique compared with equilibrium dialysis and ultracentrifugation to determine protein binding of phenytoin.

Authors:  M Oellerich; H Müller-Vahl
Journal:  Clin Pharmacokinet       Date:  1984-01       Impact factor: 6.447

6.  Plasma protein binding of valproic acid in healthy subjects and in patients with renal disease.

Authors:  R Gugler; G Mueller
Journal:  Br J Clin Pharmacol       Date:  1978-05       Impact factor: 4.335

Review 7.  Free drug concentration monitoring in clinical practice. Rationale and current status.

Authors:  C K Svensson; M N Woodruff; J G Baxter; D Lalka
Journal:  Clin Pharmacokinet       Date:  1986 Nov-Dec       Impact factor: 6.447

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.